Blood Response to Reviewers: Hematology Revision Guide

Do not answer comments as isolated tasks. Map each revision to one chain:

A new experiment can strengthen one link while leaving another unresolved. Say which link changed.

Create one ledger covering specimen source, collection time, prior treatment, processing delay, viability or quality exclusion, disease classification, molecular covariates, repeated sampling, and final analysis denominator. For flow cytometry, molecular assays, marrow versus peripheral blood, and longitudinal samples, define the biological unit explicitly.

Blood adds Key Points at revision, so treat them as a claim-control surface. A response that narrows a mechanism in the Results but leaves an absolute claim in the Key Points or abstract is internally inconsistent. Trace every changed conclusion through the title, abstract, Key Points, Results, figures, legends, and Discussion.

In our pre-submission review work with Blood manuscripts, we inspect diagnostic tables, specimen provenance, flow and molecular evidence, perturbation experiments, animal models, longitudinal outcomes, statistics, figures, source data, abstracts, and Key Points. We map every reviewer comment to the hematologic entity, specimen, model, mechanism, endpoint, and claim it tests. These are qualitative Manusights patterns, not Blood acceptance rates or confidential editorial records.

Pattern 1: classification drift changes the denominator

In Blood revisions, we often find one disease label covering cases assigned under different diagnostic systems, assay eras, or molecular thresholds. The subgroup count in the Results then differs from the flow diagram, table, or survival model. We reconcile patient-level classification, identify unclassifiable cases, and propagate the denominator through every display and claim.

Pattern 2: a molecular association becomes a mechanism

Expression, mutation, or cytokine abundance tracks outcome, but the manuscript calls it a driver. For Blood manuscripts, we look for perturbation, rescue, temporal order, lineage context, and an alternative-pathway test. If only association is supported, the response should narrow the title, Key Points, and therapeutic language.

Pattern 3: convenient models erase patient biology

A cell line or transplant model produces a clean effect but does not preserve prior treatment, immune context, clonal architecture, marrow niche, or disease stage. We require a model-transport statement and choose validation that challenges the missing feature rather than merely increasing replicate count.

Pattern 4: repeated samples inflate certainty

Serial specimens, technical wells, microscopy fields, or repeated time points are treated as independent observations. We reconstruct the hierarchy, reanalyze at the patient or animal level, and separate longitudinal evidence from cross-sectional evidence. The central result may survive while a subgroup or time-point claim does not.

The distinctive Blood information gain is chain consistency: disease entity, specimen, model, mechanism, endpoint, and claim must describe the same hematologic result.

Check the Blood response and revised evidence together.

One reviewer may ask for deeper mechanism while another asks for stronger clinical transport. Those tests answer different questions. Tell the editor which concern controls the central claim, add the most discriminating feasible evidence, and label mechanistic and clinical inferences separately. Do not merge a preclinical perturbation and an observational patient association into one causal claim.

Revision is not acceptance. Serious re-review risks include mixed or drifting disease definitions, unclear specimen timing, associative mechanism language, a model that misses the relevant disease context, pseudoreplication, unstable endpoints, selective subgroup reporting, and Key Points that overstate the revised evidence.

Most rejection-on-revision risk comes from a formally complete letter that leaves one controlling scientific concern unresolved in the manuscript.

Submit if: every comment is answered and located; diagnostic and specimen ledgers reconcile; models test the relevant uncertainty; causal language matches perturbation evidence; statistical units and longitudinal events are correct; and the abstract and Key Points match the revision.

Think twice if: the mechanism still rests on correlation, repeated samples remain independent, a larger cohort hides provenance gaps, clinical language exceeds the endpoint design, or a requested decisive experiment is merely promised.

We reviewed current Blood author, manuscript-preparation, article-type, peer-review, and journal-scope materials, then applied the evidence-chain audit above. ASH sources establish public workflow facts. The hematology evidence ledger and Manusights patterns are our analysis. The decision letter and current submission task list are authoritative for a specific manuscript.

1. Put handling-editor priorities before reviewer sections.
2. Reproduce and answer every comment and subpart.
3. Cite page, line, figure, panel, table, cohort, specimen, and supplement locations.
4. Reconcile diagnostic systems and patient-level assignments.
5. State specimen timing, treatment exposure, exclusions, and denominators.
6. Match mechanism language to perturbation and rescue evidence.
7. Use patient or animal as the statistical unit where appropriate.
8. Audit longitudinal endpoints, missingness, and competing events.
9. Synchronize response, marked and clean files, figures, abstract, and Key Points.
10. Ask for time before the stated deadline when the decisive work cannot be completed safely.

After indexation, wait for 14 final Search Console days before interpreting movement. At 21 days, keep, revise, consolidate, or stop this owner based on exact-query impressions, clicks, query fit, and qualified starts. The source cluster had 8,310 impressions and one preview start; neither proves demand for this exact query.

ASH sources establish the public revision workflow. The evidence-chain framework is Manusights interpretation.